Mostrar el registro sencillo del ítem

Eficacia de la budesonida/formoterol comparado con la fluticasona/salmeterol en la mejoría de la capacidad pulmonar de personas mayores con Enfermedad Pulmonar Obstructiva Crónica: revisión sistemática de literatura

dc.contributor.authorVargas Rodriguez, Ledmar Jovannyspa
dc.contributor.authorSolano Rojas, Flore Edalidspa
dc.contributor.authorDiaz, Sandra Lizethspa
dc.contributor.authorPinzón Olmos, Manuel Alejandrospa
dc.date.accessioned2019-07-26 00:00:00
dc.date.accessioned2022-03-08T16:18:49Z
dc.date.available2019-07-26 00:00:00
dc.date.available2022-03-08T16:18:49Z
dc.date.issued2019-07-26
dc.identifier.issn2389-7325
dc.identifier.urihttps://repositorio.uniboyaca.edu.co/handle/uniboyaca/369
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad de Boyacáspa
dc.rightsRevista Investigación en Salud Universidad de Boyacá - 2019spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0spa
dc.sourcehttps://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/369spa
dc.subjectenfermedad pulmonar obstructiva crónicaspa
dc.subjectenfisema pulmonarspa
dc.subjectbronquitis crónicaspa
dc.subjectformoterolspa
dc.subjectbudesonidaspa
dc.subjectsalmeterolspa
dc.subjectfluticasonaspa
dc.subjecteficaciaspa
dc.subjectChronic Obstructive Pulmonar Diseaseeng
dc.subjectpulmonary emphysemaeng
dc.subjectchronic bronchitiseng
dc.subjectformeteroleng
dc.subjectbudesonideeng
dc.subjectsalmeteroleng
dc.subjectfluticasoneeng
dc.subjecteffectivenesseng
dc.subjectDoença Pulmonar Obstrutiva Crônicaeng
dc.subjectenfisemaeng
dc.subjectbronquite crônicaeng
dc.subjectformoteroleng
dc.subjectbudesonidaeng
dc.subjectsalmeteroleng
dc.subjectfluticasonaeng
dc.subjecteficiênciaeng
dc.titleEficacia de la budesonida/formoterol comparado con la fluticasona/salmeterol en la mejoría de la capacidad pulmonar de personas mayores con Enfermedad Pulmonar Obstructiva Crónica: revisión sistemática de literaturaspa
dc.typeArtículo de revistaspa
dc.typeJournal articleeng
dc.identifier.doi10.24267/23897325.369
dc.identifier.eissn2539-2018
dc.identifier.urlhttps://doi.org/10.24267/23897325.369
dc.relation.bitstreamhttps://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/download/369/489
dc.relation.citationeditionNúm. 2 , Año 2019 : Revista Investigación en Salud Universidad de Boyacáspa
dc.relation.citationendpage70
dc.relation.citationissue2spa
dc.relation.citationstartpage53
dc.relation.citationvolume6spa
dc.relation.ispartofjournalRevista Investigación en Salud Universidad de Boyacáspa
dc.relation.referencesWilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med [Internet]. 2007 Nov 6 [cited 2019 Mar 11];147(9):639–53. Disponible en: https://doi.org/10.7326/0003-4819-147-9-200711060-00009 2. Brett AS, Al-Hasan MN. COPD Exacerbations — A Target for Antibiotic Stewardship. N Engl J Med [Internet]. 2019 Jul 11 [cited 2019 Jul 18];381(2):174–5. Disponible en: https://doi.org/10.1056/NEJMe1905520 3. Soriano JB. The evolution of COPD species; or, something is changing for good in COPD. Eur Respir J [Internet]. 2019 Jun 27 [cited 2019 Jul 18];53(6):1900762. Disponible en: https://doi.org/10.1183/13993003.00762-2019. 4. Zhang L, Feng W, Lu BB, Li N, Li H, Gu SH, et al. [The impact of ambient PM(2.5) on daily outpatient visits due to chronic obstructive pulmonary disease, among the urban residents of Ningbo city]. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2019 Jun 10 [cited 2019 Jul 18];40(6):686–91. Disponible en: https://doi.org/10.3760/cma.j.issn.0254-6450.2019.06.016 5. Karoli NA, Rebrov AP. Endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with coronary heart disease. Ter Arkh [Internet]. 2019 Mar 29 [cited 2019 Jul 18];91(3):22–6. Disponible en: https://doi.org/10.26442/00403660.2019.03.000061 6. Grigoryeva NY, Maiorova МV, Korolyova ME, Samolyuk MO. Сomorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Ter Arkh [Internet]. 2019 Mar 10 [cited 2019 Jul 18];91(1):38–47. Disponible en: https://doi.org/10.26442/00403660.2019.01.000027 7. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2019 Mar 11];363(12):1128–38. Disponible en: https://doi.org/10.1056/NEJMoa0909883 8. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med [Internet]. 2013 Feb 15 [cited 2019 Mar 11];187(4):347–65. Disponible en: https://doi.org/10.1164/rccm.201204-0596PP 9. Belenkov YN, Tsvetkova OA, Privalova E V., An G V., Ilgisonis IS, Voronkova OO. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers. Kardiologiia [Internet]. 2019 Jun 27 [cited 2019 Jul 18];59(6):48–55. Disponible en: https://doi.org/10.18087/cardio.2019.6.n458 10. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch Bronconeumol [Internet]. 2008 May [cited 2019 Mar 11];44(5):271–81. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18448019 11. Holleman DR, Simel DL, Goldberg JS. Diagnosis of obstructive airways disease from the clinical examination. J Gen Intern Med [Internet]. 1993 Feb [cited 2019 Mar 12];8(2):63–8. Disponible en: https://doi.org/10.1007/BF02599985 12. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. Samet J, editor. PLoS Med [Internet]. 2006 Nov 28 [cited 2019 Mar 12];3(11):e442. Disponible en: https://doi.org/10.1371/journal.pmed.0030442 13. Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc [Internet]. 2018 Oct 1 [cited 2019 Mar 12];93(10):1488–502. Disponible en: https://doi.org/10.1016/j.mayocp.2018.05.026 14. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J [Internet]. 2013 Sep 2 [cited 2019 Mar 12];42(3):559–63. Disponible en: https://doi.org/10.1183/09031936.00105513 15. Avdeev SN, Trushenko NV. New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Ter Arkh [Internet]. 2019 Mar 30 [cited 2019 Jul 18];91(3):76–85. Disponible en: https://doi.org/10.26442/00403660.2019.03.000136 16. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev [Internet]. 2014 Mar 26 [cited 2019 Mar 12];(3):CD010844. Disponible en: https://doi.org/10.1002/14651858.CD010844.pub2 17. Cohen J. A Coefficient of Agreement for Nominal Scales. Educ Psychol Meas [Internet]. 1960 Apr 2 [cited 2019 Jul 18];20(1):37–46. Disponible en: https://doi.org/10.1177/001316446002000104 18. Campo-Arias A, Herazo E. Concordancia intra-e interevaluadores. Rev Colomb Psiquiat [Internet]. 2010 [cited 2019 Jul 18];39(2):423–32. Disponible en: http://www.redalyc.org/pdf/806/80615447015.pdf 19. Tang W, Hu J, Zhang H, Wu P, He H. Kappa coefficient: a popular measure of rater agreement. Shanghai Arch Psychiatry. 2015;27(1):62–7. https://doi.org/10.11919/j.issn.1002-0829.215010 20. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med [Internet]. 2003 May [cited 2019 Jun 30];97(5):453–7. Disponible en: https://doi.org/10.1053/rmed.2002.1455 21. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology [Internet]. 2007 Sep [cited 2019 Jun 30];12(5):732–9. Disponible en: https://doi.org/10.1111/j.1440-1843.2007.01132.x 22. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis [Internet]. 2009 Aug 4 [cited 2019 Jun 30];3(4):147–57. Disponible en: https://doi.org/10.1177/1753465809344870 23. Dalby C, Polanowski T, Larsson T, Borgström L, Edsbäcker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res [Internet]. 2009 Oct 31 [cited 2019 Jul 1];10(1):104. Disponible en: https://doi.org/10.1186/1465-9921-10-104 24. World Health Organization. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects – WMA – The World Medical Association [Internet]. Helsinky; 2013 [cited 2019 Jul 18]. Disponible en: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.spa
dc.title.translatedEffectiveness of budesonide/formoterol compared to fluticasone / salmeterol in improving the lung capacity of older people with Chronic Obstructive Pulmonary Disease: systematic literature revieweng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREFspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Ficheros en el ítem

FicherosTamañoFormatoVer
Revista Investig. Salud Univ. Boyacá-369.pdf367.2Kbapplication/pdfVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Revista Investigación en Salud Universidad de Boyacá - 2019
Excepto si se señala otra cosa, la licencia del ítem se describe como Revista Investigación en Salud Universidad de Boyacá - 2019